%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-header-exterior-four-seasons-naples-beach-club-FSNAPLESBEACHCLUB0625-2b8e61cfff6e471f8b1d16f4d41914a0.jpg&w=3840&q=100)
Florida's Naples Beach Club Hotel Will Be Back This Fall as a Four Seasons—Take a First Look Inside
Taking over the renowned Naples Beach Club Hotel & Golf Club, the resort will feature 163 guest rooms, 57 suites, and 153 residences. The renovated hotel sits on 1,000 feet of sandy shoreline in Old Naples and will offer a balance of the Gulf Coast's natural beauty and local Naples charm with residential-style accommodations.
The ocean-themed guest rooms have expansive terraces with daybeds, walk-in closets, and dining nooks, alongside eye-catching decor elements such as flamingo pink or periwinkle blue lacquered cabinetry. The Resort View One Bedroom Suite features ocean-inspired interiors and expansive private terraces, allowing guests to enjoy seamless indoor-outdoor living.
Naples Beach Club, A Four Seasons Resort
'We are thrilled to unveil a brand-new resort that reinterprets the beloved destination of Naples for the next generation of guests, residents, and the local community when we open later this year,' Antoine Chahwan, the president of hotel operations for the Americas division at Four Seasons, said in a statement. 'As this highly anticipated opening comes to life, the Four Seasons culture of service and excellence will ensure an exceptional experience, further inspired by the spirit of this treasured location.'
The new Four Seasons also encompasses a 125-acre residential and golf resort, which will include The Gardens, a Tom Fazio-redesigned 18-hole golf course slated to open next year. On the residential front, Naples Beach Club will include 58 luxury condos across three beachfront buildings, while 95 luxury condos will be offered across five residential buildings facing the golf course.
'Naples Beach Club is our modern expression of the cherished traditions and style of Naples,' the resort's general manager Diego Angarita said in a statement. 'Our team cannot wait to open the doors, welcome guests and connect with the community, establishing the property as a social hub and gathering place for locals and visitors alike.'
Four Seasons tapped two-time James Beard Award winner Gavin Kaysen for The Merchant Room, Naples Beach Club's signature dining venue and his first restaurant outside the Midwest. Kaysen's arrival signals a polished-yet-approachable style to a menu of seasonal Gulf Coast–inspired dishes with French finesse, served indoors and al fresco with front-row views of the water.
24 Best Weekend Getaways in Florida
18 Best Family Beaches in Florida The resort's oceanfront Sunset Bar.
Naples Beach Club, A Four Seasons Resort
Another venue is one that guests and locals are likely to recognize. HB's, the beloved beachfront, returns with a breezy makeover and a toes-in-the-sand vibe. It is named for Henry B. Watkins, who founded the original Naples Beach Hotel, and pays homage to the past in a space built for sunset seafood feasts and barefoot cocktails. Sunset Bar is also planned for a revival in the new hotel, reclaiming its status as the go-to spot in town for golden hour with a mai tai on the side.
Naples Beach Club guests will also have access to Market Square, a multifaceted bazaar that includes Naples Trading Company for grab-and-go provisions as well as entertainment options, such as a four-lane bowling alley, private screening room, game room, and a putting green. Market Square also features the supervised FINS Club for Kids, a mix of open-air and indoor event spaces, and, beginning in 2026, The Wager, a sports pub.
Those looking for more laid-back vibes can enjoy a treatment at the 30,000-square-foot Sanctuary Spa with a rooftop lap pool and a Harley Pasternak-designed gym.
This being Naples, the star of the show is obviously the beach. Attentive staffers will be on hand for towel drops and spritz refills, as well as to help arrange water sports or beach games. Save at least one sunset for aboard the 34-foot classic Hinckley Picnic Boat, offered exclusively to hotel guests. Those who are more about pool time than splashing in the Gulf can enjoy two different options, both surrounded by loungers and private cabanas. A family-friendly splash area is also available.
Guests who like to venture off-site can enjoy a variety of experiences, ranging from exploring Everglades National Park to shopping Fifth Avenue South in downtown Naples, or attending a night at the Naples Philharmonic.
Nightly rates at Naples Beach Club, a Four Seasons Resort start at $1,100. Reservations are now open for stays beginning November 24, 2025, and can be booked on fourseasons.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
U.S. Hiring Was Weak in July, With 73,000 Jobs Added
U.S. job growth slowed in July, a signal that pockets of weakness that had been marring the labor market are starting to take hold. The U.S. added a seasonally adjusted 73,000 jobs in July, the Labor Department reported Friday, below the gain of 100,000 jobs economists polled by The Wall Street Journal had expected to see. Why Ford's Made-in-America Strategy Hurts It in Trump's Trade War Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a Billionaire Community Callout: What Would You Ask a Mega-Millionaire About Money? Big Tech's $400 Billion AI Spending Spree Just Got Wall Street's Blessing Amazon Shares Fall Because Cloud Unit's Growth Wasn't Enough for Wall Street The unemployment rate rose slightly to 4.2% from 4.1%. Hiring in May and June was much weaker than previously reported. Revisions showed employers added a combined 258,000 fewer jobs in May and June than previously estimated. July's report comes as economists and policymakers are trying to figure out which of two competing narratives about the economy is more true. One view is that of surprising resilience. Tariff threats, though they have started to seep into some prices, have yet to translate into pronounced inflation. Consumers, after holding back earlier in the year, are feeling a bit more confident. The other perspective is that cracks are starting to appear and could deepen. Some companies, such as Procter & Gamble and Chipotle Mexican Grill, are reporting that customers are becoming more sensitive to prices. Young consumers in particular are cutting back on discretionary spending, and much of the economy's growth is being driven by the wealthiest Americans. 'Everyone is trying to understand what direction the economy is taking,' said Jonathan Pingle, chief U.S. economist at UBS. Guy Berger, senior fellow at labor-market think tank Burning Glass Institute, is of the opinion that the economy is still stable. 'You look at almost every major indicator,' Berger said, 'and they have all been pretty steady since last fall.' One factor that hasn't been steady, though, is the policy backdrop. 'I would not bet a lot of money on things staying stable going forward,' Berger said, citing tariffs, restrictions on immigration and a big new tax bill. Economists are paying particular attention to changes in the supply of workers. A dramatic decrease in border crossings is constraining the number of people from abroad coming into the labor force. High-profile immigration raids are keeping many workers at home. Meanwhile, the U.S. is aging, boosting retirements and limiting the number of younger people joining the workforce. A year and a half ago, the economy needed to add 166,000 jobs a month to keep the labor market steady, according to Peterson Institute for International Economics senior fellow Jed Kolko. As of June, Kolko said, the needed number was only 86,000. 'It's fallen so much because this immigration surge has ended,' Kolko said. In other words, a job creation number that might have looked lackluster a year and a half ago might actually be strong today. Recently, the number of jobs created each month has been slowing, but the unemployment rate has risen only slightly. 'People are going to have to get used to employment gains that are meh that will not tell us on their own that the job market is weak,' said Berger. 'That is a weird thing for people to get used to.' Write to Rachel Wolfe at Shake Shack Leans Into Innovation to Keep Customers Coming Figma Shares Jump 250% in Their Stock-Market Debut Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs UnitedHealth Group Replaces CFO John Rex Here's How Companies Are Dealing With $50 Billion of New Tariffs Sign in to access your portfolio
Yahoo
3 minutes ago
- Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Revived Trade War Fears
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.8% and the actively tr Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Moderna's Key Patent Win Overshadowed By Gloomy Outlook
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million. Sales fell 41% from $241 million in the same period in 2024. The decline was primarily driven by lower COVID-19 vaccine sales, which totaled $114 million in the is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine transitions into a seasonal respiratory product. The company reported $114 million in Spikevax sales in the second quarter of 2025, including $88 million in U.S. and $26 million in international sales. Moderna recently announced U.S. Food and Drug Administration (FDA) approval for the supplemental Biologics License Application (sBLA) for Spikevax in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The company's COVID-19 vaccine (mRNA-1273) was previously available for pediatric populations under Emergency Use Authorization (EUA). Additionally, the company announced it has received final approval from the European Medicines Agency for Spikevax targeting the LP.8.1 variant in individuals six months of age and older. Moderna also announced FDA approval for mNEXSPIKE (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor. On Wednesday, the European Commission approved the updated formulation of the COVID-19 vaccine Spikevax, targeting the SARS-CoV-2 variant LP.8.1, for individuals six months of age and older. Moderna reported negligible mRESVIA (RSV vaccine) sales in the second quarter of 2025. Moderna's RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries. Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. View more earnings on MRNA Cost of sales for the second quarter of 2025 was $119 million, which included third-party royalties of $6 million, inventory write-downs of $38 million, and unutilized manufacturing capacity and wind-down costs of $52 million. Cost of sales was relatively flat compared to the same period in 2024. The increase in cost of sales as a percentage of net product sales, to 105% from 62% in the second quarter of 2024, was mainly driven by lower net product sales. R&D expenses were $700 million, a 43% decrease year over year. The reduction was primarily driven by lower clinical trial and manufacturing expenses, reflecting reduced production spending, program wind-downs, and the timing of trial activities across the company's respiratory vaccine portfolio. Outlook Moderna has revised its 2025 revenue outlook to $1.5 billion-$2.2 billion compared to $1.5 billion-$2.5 billion, compared to a consensus of $2.09 billion, reflecting a $300 million reduction at the high end of the range. The update is primarily driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. Moderna expects a revenue split of 40-50% in the third quarter for the second half of the year, with the balance in the fourth quarter of 2025. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of under 5,000 by year-end. Legal Ruling On Friday, Moderna announced that the U.K. Court of Appeal upheld the validity of Moderna's EP'949 patent. European patent EP'949 relates to chemically modified mRNA, one of Moderna's foundational technologies. The decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) COVID-19 vaccine, Comirnaty. Pfizer/BioNTech subsequently appealed. With this ruling, the U.K. becomes the first jurisdiction globally to issue a second-instance decision confirming the validity of one of Moderna's core mRNA patents. In Germany, the Regional Court found that Pfizer and BioNTech infringed Moderna's modified mRNA patent and confirmed Moderna's right to seek damages. An appeal is pending. The European Patent Office upheld the validity of EP'949 in opposition proceedings. An appeal is pending. Price Action: Moderna stock is trading 7.92% lower to $27.22 premarket at last check Friday. Read Next:Photo by Lutsenko_Oleksandr via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? MODERNA (MRNA): Free Stock Analysis Report This article Moderna's Key Patent Win Overshadowed By Gloomy Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
